Almér L O
Thromb Res. 1984 Jul 1;35(1):19-25. doi: 10.1016/0049-3848(84)90309-8.
The components of the fibrinolytic system were studied in patients with maturity onset diabetes, treated with chlorpropamide for three years or more. Half of the patients (7/15) were shown to have abnormally low plasminogen activator activity of the vascular walls. The patients were then shifted to gliclazide, a new sulfonylurea, and after six months all patients had a normal vascular plasminogen activator activity. At follow up after 24 and 48 months the results remained the same. The normalization of the vascular fibrinolytic defence system could not be explained by improvement of glucose control.
对使用氯磺丙脲治疗三年及以上的成年发病型糖尿病患者的纤溶系统成分进行了研究。一半的患者（7/15）显示血管壁纤溶酶原激活物活性异常低。然后这些患者改用新型磺脲类药物格列齐特，六个月后所有患者的血管纤溶酶原激活物活性恢复正常。在24个月和48个月的随访中，结果保持不变。血管纤溶防御系统的正常化无法用血糖控制的改善来解释。
